UroGen Pharma Ltd.
Clinical trials sponsored by UroGen Pharma Ltd., explained in plain language.
Develops therapies for urological cancers and diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer gel shows promise for rare urinary tract tumors Results expected Mar 2027 (estimated) 🚀 Make-or-break
-
Chemo gel delivered directly to kidney tumors: can it help when other options run out?
Disease control Expanded accessThis named patient program gives doctors controlled, pre-approval access to a mitomycin gel called JELMYTO for specific patients with cancer of the renal pelvis or ureter. It is for people in select countries where the treatment is not yet approved and who have exhausted other op…
Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer gel shows promise for rare urinary tract tumors
Disease control Recruiting nowThis study tests a new gel-like drug, UGN-104, placed directly into the upper urinary tract to treat low-grade cancer. About 70 adults with small tumors will receive the treatment to see if it can completely eliminate visible cancer. The goal is to control the disease and avoid m…
Phase 3 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC